Figure 6
Anti-ULBP3 monoclonal antibody enhances the activity of NK cells from cancer patients via ADCC.
ULBP3 expression and the percentage of infiltrating NK cells in tumor tissues from 10 patients (4 colorectal cancer, 3 lung cancer and 3 gastric cancer) were determined by FCM. A representative graph is shown in (A). The relationship between ULBP3 expression and infiltrating NK cells in tumor tissues is shown in (B). Normal NK cells were co-cultured with CD133−SW620 (C) or 7721 (D) cells at the indicated E:T ratios and cytotoxicity was measured by LDH release after 6 h of co-culture, with or without the addition of isotype IgG, anti-ULBP3 (B2-F1-F1), and/or anti-CD16 (5 μg/ml). K562 (E) or A549 (F) cells were co-cultured with normal NK cells and cytotoxicity was measured by LDH release after 6 h of co-culture at the indicated E:T ratios, with or without the addition of ULBP3-Fc (1 ng/ml) and/or B2-F1-F1 (5 μg/ml). The data are representative of results obtained from at least 3 independent experiments. The results are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
